Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Professional Survey Report 2018

Table of Contents

Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Professional Survey Report 2017

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Preface Market Performance (Volume)
  • 2.1.2 Eluxadoline Market Performance (Volume)
  • 2.1.3 Alosetron Market Performance (Volume)
  • 2.1.4 Rifaximin Market Performance (Volume)
  • 2.1.5 Loperamide Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Preface Market Performance (Value)
  • 2.1.2 Eluxadoline Market Performance (Value)
  • 2.1.3 Alosetron Market Performance (Value)
  • 2.1.4 Rifaximin Market Performance (Value)
  • 2.1.5 Loperamide Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Hospitals Market Performance (Volume)
  • 3.1.2 Clinics Market Performance (Volume)
  • 3.1.3 Others Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Astellas Pharmaceuticals
  • 4.1.1 Astellas Pharmaceuticals Profiles
  • 4.1.2 Astellas Pharmaceuticals Product Information
  • 4.1.3 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
  • 4.1.4 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
• 4.2 Actavis
  • 4.2.1 Actavis Profiles
  • 4.2.2 Actavis Product Information
  • 4.2.3 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
  • 4.2.4 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
• 4.3 Pfizer
  • 4.3.1 Pfizer Profiles
  • 4.3.2 Pfizer Product Information
  • 4.3.3 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
  • 4.3.4 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
• 4.4 GlaxoSmithKline
  • 4.4.1 GlaxoSmithKline Profiles
  • 4.4.2 GlaxoSmithKline Product Information
  • 4.4.3 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
  • 4.4.4 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
• 4.5 Salix Pharmaceuticals Ltd
  • 4.5.1 Salix Pharmaceuticals Ltd Profiles
  • 4.5.2 Salix Pharmaceuticals Ltd Product Information
  • 4.5.3 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
  • 4.5.4 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status
• 4.6 AstraZenenca
  • 4.6.1 AstraZenenca Profiles
  • 4.6.2 AstraZenenca Product Information
  • 4.6.3 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Performance
  • 4.6.4 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Business Development and Market Status

5 Market Performance for Manufacturers

• 5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
• 5.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
• 5.6 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 China Market Performance for Manufacturers
  • 6.1.1 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 USA Market Performance for Manufacturers
  • 6.2.1 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 Europe Market Performance for Manufacturers
  • 6.3.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Japan Market Performance for Manufacturers
  • 6.4.1 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Korea Market Performance for Manufacturers
  • 6.5.1 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 India Market Performance for Manufacturers
  • 6.6.1 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Southeast Asia Market Performance for Manufacturers
  • 6.7.1 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 South America Market Performance for Manufacturers
  • 6.8.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Performance (Sales Point)

• 7.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units) and Market Share by Regions 2013-2018
• 7.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales (K Units) and Market Share by Regions 2013-2018
• 7.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (M USD) and Market Share by Regions 2013-2018
• 7.4 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) by Regions 2013-2018
• 7.5 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018
• 8.9 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity and Growth, Sales Value and Growth Rate2013-2018

9 Development Trend for Regions (Sales Point)

• 9.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.3 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.4 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.5 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.6 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.7 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.8 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018
• 9.9 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth, Sales Value and Growth Rate2013-2018

10 Upstream Source, Technology and Cost

• 10.1 Upstream Source
• 10.2 Technology
• 10.3 Cost

11 Channel Analysis

• 11.1 Market Channel
• 11.2 Distributors

12 Consumer Analysis

• 12.1 Hospitals Industry
• 12.2 Clinics Industry
• 12.3 Others Industry

13 Market Forecast 2019-2024

• 13.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 13.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units) and Share by Regions 2019-2024
  • 13.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units) and Growth Rate 2019-2024
  • 13.1.3 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.4 USA Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.5 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.6 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.7 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.8 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.9 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.1.10 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Capacity (K Units), Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 13.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 13.3.1 Overall Market Performance
  • 13.3.2 Preface Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.3.3 Eluxadoline Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.3.4 Alosetron Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 13.3.5 Rifaximin Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 13.4 Sales by Application 2019-2024
  • 13.4.1 Overall Market Performance
  • 13.4.2 Hospitals Sales and and Growth Rate 2019-2024
  • 13.4.3 Clinics Sales and and Growth Rate 2019-2024
  • 13.4.4 Others Sales and and Growth Rate 2019-2024
• 13.5 Price (USD/Unit) and Gross Profit
  • 13.5.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price (USD/Unit) Trend 2019-2024
  • 13.5.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Gross Profit Trend 2019-2024

14 Conclusion